EGF and non-small cell lung carcinoma: Cetuximab is a human-mouse chimeric IgG1 anti-EGFR-mAb that selectively binds to EGFR, competitively inhibits its binding to endogenous ligands and inhibits the activation of epidermal growth factor (EGF) and downstream intracellular signal transduction.[15] The FLEX trial[16] showed that adding an anti-EGFR-mAb, cetuximab, to vincristine and cisplatin chemotherapy in the first-line treatment of patients with NSCLC expressing EGFR remarkably improved OS (median, 11.3 months vs 10.1 months, HR = 0.871, 95%CI: 0.762-0.996, P = .044).